Tubidy

    Debra Patt, MD, on why it is important for community oncologists to partner with associations

    01:12 •
    Debra Patt, MD, on why it is important for community oncologists to partner with associations
    Download MP3

    Related Videos

    Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

    Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

    Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

    Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

    Michael Diaz, MD, on how community oncology is shaping the future of cancer care

    Michael Diaz, MD, on how community oncology is shaping the future of cancer care

    Brad Prechtl tells how his practice is working to improve cancer care

    Brad Prechtl tells how his practice is working to improve cancer care

    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

    The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

    The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

    Lee Schwartzberg, MD, on whether clinical trial experience with I-O translates to routine care

    Lee Schwartzberg, MD, on whether clinical trial experience with I-O translates to routine care

    Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

    Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

    Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

    Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

    Lalan Wilfong, MD, shares knowledge on how to thrive in the rapidly evolving APM landscape

    Lalan Wilfong, MD, shares knowledge on how to thrive in the rapidly evolving APM landscape

    Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

    Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

    Brian Slomovitz, MD, elaborates on the role of immunotherapy in ovarian cancer

    Brian Slomovitz, MD, elaborates on the role of immunotherapy in ovarian cancer

    Steven D'Amato, BSPharm, describes best practices and new programs being adopted to treat patients

    Steven D'Amato, BSPharm, describes best practices and new programs being adopted to treat patients

    Sibel Blau, MD, tells us more about IQ Oncology

    Sibel Blau, MD, tells us more about IQ Oncology

    Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

    Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

    Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

    Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

    Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

    Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

    Kerin Adelson, MD, on understanding what drives the cost of cancer care

    Kerin Adelson, MD, on understanding what drives the cost of cancer care

    Roy Beveridge, MD, explains how Humana works with cancer stakeholders to develop treatment models

    Roy Beveridge, MD, explains how Humana works with cancer stakeholders to develop treatment models

    Robert J. Brooks, MD, describes OneOncology's welcoming and impressive treatment resources

    Robert J. Brooks, MD, describes OneOncology's welcoming and impressive treatment resources